JC-171 is an NLRP3 inflammasome inhibitor with biological activity in vivo, for potential treatment of multiple sclerosis. JC-171 treatment was shown to delay the progression and reduce the severity of experimental autoimmune encephalomyelitis (EAE), and a mouse model of MS, in both prophylactic and therapeutic settings. References: Guo C, Fulp JW, Jiang Y, Li X, Chojnacki JE, Wu J, Wang XY, Zhang S. Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis. ACS Chem Neurosci. 2017 Oct 18;8(10):2194-2201. doi: 10.1021/acschemneuro.7b00124. Epub 2017 Jul 13. PubMed PMID: 28653829; PubMed Central PMCID: PMC5672903.

纯度：≥98%

CAS：2112809-98-8